Since trastuzumab deruxtecan is the only drug for which survival prolongation was confirmed in comparison with chemotherapy regimens in third-line treatment, trastuzumab deruxtecan is prioritized for third-line therapy of HER2-positive gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.